# Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis

> **NCT00854087** · PHASE2 · COMPLETED · sponsor: **Tarek Hassanein** · enrollment: 118 (actual)

## Conditions studied

- Chronic Hepatitis C Infection

## Interventions

- **DRUG:** Fuzheng Huayu
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00854087
- **Lead sponsor:** Tarek Hassanein
- **Sponsor class:** INDIV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2013-04
- **Final completion:** 2013-08
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2021-05-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00854087

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00854087, "Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00854087. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*